IGC Pharma (IGC) Non-Current Deferred Tax Liability (2011 - 2012)
IGC Pharma (IGC) posted quarterly Non-Current Deferred Tax Liability of $713897.0 for Q4 2012, little changed year-over-year from $713897.0 in Q1 2012, and little changed quarter-over-quarter from $713897.0 in Q3 2012.
IGC Pharma (IGC) Non-Current Deferred Tax Liability (2011 - 2012) Analysis & Trends
IGC Pharma (IGC) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $713897.0 the latest figure, recorded in Q4 2012.
- In Q4 2012, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $713897.0; the TTM figure through Dec 2012 stood at $713897.0 (changed 0.0% YoY), while the FY2012 annual figure was $713897.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability steadied at $713897.0 in Q4 2012 per IGC's latest filing, from $713897.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $713897.0 in Q4 2011 and bottomed at $713897.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 713,897.00 |
| Dec 31, 2012 | 713,897.00 |
| Sep 30, 2012 | 713,897.00 |
| Sep 30, 2012 | 713,897.00 |
| Jun 30, 2012 | 713,897.00 |
| Jun 30, 2012 | 713,897.00 |
| Mar 31, 2012 | 713,897.00 |
| Mar 31, 2012 | 713,897.00 |
| Dec 31, 2011 | 713,897.00 |
| Dec 31, 2011 | 713,897.00 |